

## Akums Drugs & Pharmaceuticals IPO

**Akums Drugs and Pharmaceuticals IPO Price:** ₹646 to ₹679 per share  
**IPO Dates:** 30 July 2024 - 1 August 2024



### Company Overview

Established in 2004, Akums Drugs and Pharmaceuticals Limited is a leading pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.

### Services and Capabilities

The company provides comprehensive end-to-end solutions for product development, manufacturing, research and development (R&D) of formulations, and preparation and submission of regulatory dossiers in both Indian and global markets. It also offers various testing services. Additionally, Akums is involved in manufacturing and selling branded drugs and active pharmaceutical ingredients (APIs).

As a CDMO, Akums manufactures a diverse range of dosage forms, including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections, and gummy bears. The company holds intellectual property rights for the manufacturing processes of several of its formulations. Its primary focus is on delivering end-to-end product development and manufacturing solutions to its clients, along with formulation research, regulatory dossier preparation and filing, and other testing services.

### Achievements and Production Capacity

Akums has produced a total of 4,025 commercialized formulations in over 60 dosage forms. In the financial year 2023, the company manufactured formulations for 26 of India's top 30 pharmaceutical companies by revenue. For its CDMO business, Akums operates 10 manufacturing units with a cumulative production capacity of 49.21 billion units annually as of September 30, 2023.

The company plans to expand its production capacity with two additional production units to be commissioned in FY 2025. Some of its production facilities have been

accredited by various global regulatory bodies, such as the European Good Manufacturing Practice (EU-GMP), the World Health Organization Good Manufacturing Practice (WHO-GMP), and the United States National Sanitation Foundation (US NSF).

## Market Position

Akums is the largest India-focused CDMO in terms of revenue, production capacity, and clients served during the financial year 2023, according to the F&S Report. During the financial year 2024, Akums held a 30.2% market share of the Indian domestic CDMO market by value, up from 26.7% in the financial year 2021.

## Don't Miss Out!

Whether you're a seasoned investor or just starting out, Lakshmishree ensures you don't miss out on premier IPO opportunities. Dive into the future of investing with Lakshmishree.

**APPLY NOW**

## Akums Drugs and Pharmaceuticals IPO Specifics:

IPO Date	July 30, 2024 to August 1, 2024
Listing Date	Tuesday, August 6, 2024
Face Value	₹2 per share
Price Band	₹646 to ₹679 per share
Lot Size	22 Shares
Total Issue Size	27,345,162 shares (aggregating up to ₹1,856.74 Cr)
Fresh Issue	10,014,727 shares (aggregating up to ₹680.00 Cr)
Offer For Sale	17,330,435 shares (aggregating up to ₹1,176.74 Cr)
Employee Discount	Rs 64 per share
Issue Type	Book Built Issue IPO
Listing At	BSE, NSE
Share holding pre issue	147,356,280
Share holding post issue	157,371,007

## Akums Drugs and Pharmaceuticals IPO Lot Size

Bidders have the opportunity to bid for a minimum of 22 shares, with the option to increase in multiples. The table below outlines the minimum and maximum investment thresholds for both retail investors and High Net Worth Individuals (HNIs), specifying the corresponding number of shares and amounts involved.

Application	Lots	Shares	Amount
Retail (Min)	1	22	₹14,938
Retail (Max)	13	286	₹194,194
S-HNI (Min)	14	308	₹209,132
S-HNI (Max)	66	1,452	₹985,908
B-HNI (Min)	67	1.474	₹1,000,846

## Akums Drugs and Pharmaceuticals IPO Reservation

QIB Shares Offered	Not more than 75% of the Net offer
Retail Shares Offered	Not less than 10% of the Offer
NII (HNI) Shares Offered	Not less than 15% of the Offer

## Akums Drugs and Pharmaceuticals IPO Timetable (Important Dates)

IPO Open Date	Tuesday, July 30, 2024
IPO Close Date	Thursday, August 1, 2024
Basis of Allotment	Friday, August 2, 2024
Initiation of Refunds	Monday, August 5, 2024
Credit of Shares to Demat	Monday, August 5, 2024
Listing Date	Tuesday, August 6, 2024
Cut-off time for UPI mandate confirmation	5 PM on August 1, 2024

# Akums Drugs and Pharmaceuticals Limited IPO

## Financial Information

Akums Drugs and Pharmaceuticals Limited witnessed a 13.81% growth in revenue, while the profit after tax (PAT) declined by -99.19% from the financial year ending on March 31, 2024, compared to March 31, 2023.

Period Ended	31 Mar 2022	31 Mar 2023	31 Mar 2024
Assets	3069.05	3266.53	3516.37
Revenue	3694.52	3700.93	4212.21
Profit After Tax	-250.87	97.82	0.79
Net Worth	621.98	717.79	709.50
Reserves & Surplus	787.79	868.70	861.01
Total Borrowing	868.70	536.97	491.56

Amount in ₹ Crore

## Key Performance Indicator - Akums Drugs and Pharmaceuticals IPO

KPI	Values
ROE	0.11%
ROCE	3.37%
Debt/ Equity	0.69
RoNW	-0.57%
P/BV	13.69
PAT Margin	0.02%

## Objects of the Issue:

The company intends to use the net proceeds for the following purposes:

1. Repaying or prepaying debts of the company and its subsidiaries.
2. Pursuing growth opportunities through acquisitions.
3. Meeting additional working capital needs.
4. General corporate purposes.

## Prospectus Links:

**Prospectus:** Official documents that provide detailed information about the IPO and the company.

[Akums Drugs and Pharmaceuticals Limited DRHP](#)

[Akums Drugs and Pharmaceuticals Limited RHP.](#)